RVTY - Latest News
Revvity, Inc. (RVTY), operates in Healthcare / Medical - Diagnostics & Research, trades on NYSE.
Market capitalization stands near $10.62B. Trailing twelve-month P/E ratio is 44.11. Beta to the broader market is 1.05.
The article list below shows the most recent RVTY headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RVTY Headlines
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
zacks.com - May 14, 2026
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 13, 2026
Revvity, Inc.
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
businesswire.com - May 13, 2026
WALTHAM, Mass. --(BUSINESS WIRE)--Revvity, Inc.
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
zacks.com - May 5, 2026
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 5, 2026
Revvity, Inc.
How News Affects RVTY Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RVTY's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RVTY news questions
- What is the latest RVTY news headline?
- The most recent RVTY headline (May 14, 2026) is "RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RVTY news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RVTY news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RVTY options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.